PE20081317A1 - Formas de cristal de la epotilona b - Google Patents

Formas de cristal de la epotilona b

Info

Publication number
PE20081317A1
PE20081317A1 PE2007001090A PE2007001090A PE20081317A1 PE 20081317 A1 PE20081317 A1 PE 20081317A1 PE 2007001090 A PE2007001090 A PE 2007001090A PE 2007001090 A PE2007001090 A PE 2007001090A PE 20081317 A1 PE20081317 A1 PE 20081317A1
Authority
PE
Peru
Prior art keywords
epotilone
crystal forms
intensity
refers
values
Prior art date
Application number
PE2007001090A
Other languages
English (en)
Spanish (es)
Inventor
Ernst Kusters
Michael Mutz
Frank Stowasser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37685905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081317(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20081317A1 publication Critical patent/PE20081317A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2007001090A 2006-08-16 2007-08-14 Formas de cristal de la epotilona b PE20081317A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06119043 2006-08-16

Publications (1)

Publication Number Publication Date
PE20081317A1 true PE20081317A1 (es) 2008-10-28

Family

ID=37685905

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001090A PE20081317A1 (es) 2006-08-16 2007-08-14 Formas de cristal de la epotilona b

Country Status (22)

Country Link
US (1) US8178566B2 (enExample)
EP (1) EP2064216A2 (enExample)
JP (1) JP2010500387A (enExample)
KR (1) KR20090038902A (enExample)
CN (1) CN101506217B (enExample)
AR (1) AR062375A1 (enExample)
AU (1) AU2007286454A1 (enExample)
BR (1) BRPI0715963A2 (enExample)
CA (1) CA2658475A1 (enExample)
CL (1) CL2007002362A1 (enExample)
IL (1) IL196558A0 (enExample)
MA (1) MA30656B1 (enExample)
MX (1) MX2009001635A (enExample)
MY (1) MY148355A (enExample)
NO (1) NO20091081L (enExample)
NZ (1) NZ574194A (enExample)
PE (1) PE20081317A1 (enExample)
RU (1) RU2009109352A (enExample)
TN (1) TN2009000044A1 (enExample)
TW (1) TW200815455A (enExample)
WO (1) WO2008019820A2 (enExample)
ZA (1) ZA200900227B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110300150A1 (en) 2010-05-18 2011-12-08 Scott Eliasof Compositions and methods for treatment of autoimmune and other disease
CN103910742B (zh) * 2013-01-07 2016-07-13 浙江海正药业股份有限公司 一种制备埃博霉素b无定形粉末的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200002299T2 (tr) 1998-02-05 2000-11-21 Novartis Ag Epotilon kompozisyonları.
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
GB0029895D0 (en) 2000-12-07 2001-01-24 Novartis Ag Organic compounds
AU2003275068B2 (en) * 2002-09-23 2009-09-17 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone B, and X-Ray crystal structures of epothilone B

Also Published As

Publication number Publication date
CN101506217A (zh) 2009-08-12
WO2008019820A3 (en) 2008-04-17
KR20090038902A (ko) 2009-04-21
RU2009109352A (ru) 2010-09-27
JP2010500387A (ja) 2010-01-07
ZA200900227B (en) 2009-12-30
CN101506217B (zh) 2012-09-05
MY148355A (en) 2013-03-29
US20100160393A1 (en) 2010-06-24
CL2007002362A1 (es) 2008-08-08
CA2658475A1 (en) 2008-02-21
MA30656B1 (fr) 2009-08-03
NZ574194A (en) 2011-12-22
BRPI0715963A2 (pt) 2013-08-06
EP2064216A2 (en) 2009-06-03
WO2008019820A2 (en) 2008-02-21
MX2009001635A (es) 2009-02-23
IL196558A0 (en) 2009-11-18
NO20091081L (no) 2009-03-16
US8178566B2 (en) 2012-05-15
AR062375A1 (es) 2008-11-05
TW200815455A (en) 2008-04-01
TN2009000044A1 (en) 2010-08-19
AU2007286454A1 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
AU2016202535B2 (en) Fused heterocyclic compounds as sodium channel modulators
PH12013502549B1 (en) Fused benzoxazepinones as ion channel modulators
AR112816A2 (es) Compuestos que inhiben el enlace de la proteína smac al inhibidor de proteínas de apoptosis (iap)
MX338916B (es) Oxazepinas como moduladores del canal de iones.
MX2019012756A (es) Compuestos de heteroarilo biciclicos 6-6 fusionados y su uso como inhibidores de lats.
EA026385B9 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
EA201290988A1 (ru) Стереоселективный синтез фосфорсодержащих активных соединений
PE20142353A1 (es) Ansolvatos de sal de noribogaina
EA201001555A1 (ru) Антиоксидативные модуляторы воспаления: производные олеанолевой кислоты с аминовыми и другими модификациями на с-17
CN103717571B8 (zh) 9‑氨基甲基取代的四环素类化合物
CN102036649A8 (zh) 精氨酸盐及其治疗口腔疾病的用途
BR112016011065A8 (pt) composto cristalino, composição farmacêutica, forma de dosagem, método para tratar anemia
EA201491623A1 (ru) Замещенные пирролидин-2-карбоксамиды
CL2013002341A1 (es) Compuestos derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4 d]pirimidin-4-ona, inhibidores de pde9a; composicion farmaceutica; y su uso para el tratamiento de una enfermedad o afección relacionado con deterioro cognitivo, enfermedad de alzheimer, demencia vascular, entre otros
WO2013028818A8 (en) Pyrimido- pyridazinone compounds and use thereof
JP2013528182A5 (enExample)
WO2010139979A3 (en) Processes for preparing crystalline forms of dasatinib
AR080490A1 (es) FORMAS CRISTALINAS DE UN INHIBIDOR DE ELASTASA NEUTROFILA, COMPOSICIoN FARMACEUTICA QUE LAS COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE ALFA-1-ANTITRIPSINA
CL2013000735A1 (es) Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para el tratamiento de enfermedades y condiciones de la piel, tales como rosacea, daño solar cronico, psoriasis, entre otras; kit farmaceutico.
AR080275A1 (es) Formas solidas de un derivado de n-( fenilmetil) propanamida y procedimientos de preparacion
CL2013000756A1 (es) Forma cristalaina del citrato diacido de (4s)-4-(5-fenil-1,3,4-tiadiazol-2-iloxi)-1-azatriciclo[3.3.1.13,7]decano; proceso de preparacion; composicion farmaceutica; y su uso para tratar o prevenir un trastorno de la memoria, un trastorno cognitivo, neurodegeneracion, entre otros.
AR057099A1 (es) Una forma cristalina, un proceso de preparacion y composicion farmaceutica
ES2650604T3 (es) Nueva forma cristalina VII de agomelatina, método de preparación y utilización de la misma, así como composición farmacéutica que la contiene
BR112013017757A2 (pt) derivado de oxazina cristalino e seu uso como inibidor de bace
PE20081317A1 (es) Formas de cristal de la epotilona b

Legal Events

Date Code Title Description
FC Refusal